Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: Product News

Product News

3 Image Protein Control Red Top IMM Vial 3 01

Liquid Immunology Control from Randox

, 26 August 2020/in Product News /by 3wmedia

The Randox Acusera Immunology control is both flexible and comprehensive covering a total of 27 serum proteins including AFP, RF, Total & Free Kappa and Lambda light chains.  The liquid ready-to-use format of the control makes it not only easy and convenient to handle but eliminates the need to thaw before use.  As an assayed protein control method specific target values are provided for both immunoturbidimetric and nephelometric methods. 

  • Liquid ready-to-use
  • 100% human serum providing a matrix similar to patient samples
  • Three levels available spanning the clinical range
  • Third party control for an independent, unbiased assessment of performance
  • Open vial stability of 30 days at +2-8oC keeps waste to a minimum

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/3-Image-Protein-Control-Red-Top-IMM-Vial-3_01.jpg 150 54 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:43Liquid Immunology Control from Randox
C259 CorisBioConcept Surra Sero K SeT

Immunochromatographic test for T. evansi-specific antibodies

, 26 August 2020/in Product News /by 3wmedia

Infection with Trypanosoma evansi causes the disease ‘surra’ that affects a wide variety of wild and domesticated animals in India, Africa, Asia, and Latin America, and outbreaks also occur sporadically in Europe. Pyrexia and progressive anemia are major clinical signs of surra, and the principal host species are camels, horses, buffaloes and cattle. Detection of antibodies specific to T. evansi is possible with immunofluorescence (IFA), enzyme linked immunosorbent assay (ELISA) and a card agglutination test (CATT/T.evansi). In collaboration with the Institute of Tropical Medicine (Antwerp, Belgium), Coris BioConcept has developed an immunochromatography test (ICT) for detecting antibodies specific for T. evansi. First validation performed on 88 positives and 73 negatives shows a negative predictive value (NPV) of 100 %. The test is performed in 15 minutes on whole blood or plasma. It is the first ICT test for surra that is intended to be used either in the laboratory or in the field.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C259_CorisBioConcept_Surra-Sero-K-SeT.jpg 127 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:20Immunochromatographic test for T. evansi-specific antibodies
siemens

Urine chemistry analyser

, 26 August 2020/in Product News /by 3wmedia

Urinalysis plays a key role in the central lab setting as a non-invasive and cost effective way to detect early kidney disease, urinary tract infections, diabetes and liver dysfunction. Since urinalysis samples come from a variety of collection sites (nursing homes, out-patient clinics, emergency departments), at all times of the day and night, laboratorians need a simple solution to manage high volumes while delivering consistent, reliable results. The CLINITEK Novus automated urine chemistry analyser is now available in Europe. The instrument combines proven dry-pad urine chemistry technology with an easy-to-use cassette test format, helping laboratories deliver reliable, trusted test results while maximising productivity. Offering a full spectrum of tests and a throughput of up to 240 samples per hour, the analyser streamlines workflow, simplifies routine analysis and STAT testing and delivers consistent, high-quality results, even during peak periods. A digital imaging measurement system is utilised to improve accuracy of results, and new ergonomic features such as the tiltable, colour-touch screen and intuitive user interface, customised menu options, simplified, cassette-based test handling and automatic entry of cassette lot number and expiration date enhance ease-of-use. All CLINITEK analysers use the same proven testing technology, regardless of test format. This helps ensure confidence in test results in every setting, from point-of-care locations to highvolume automated laboratories.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/siemens.jpg 77 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:28Urine chemistry analyser
C179

Listeria monoclonal antibodies

, 26 August 2020/in Product News /by 3wmedia

Listeriosis is a serious infection caused by the bacterium Listeria monocytogenes. This infection is contracted by eating contaminated food. The infection can lead to miscarriage, stillbirth and meningitis. An outbreak in 2011 involving contaminated cantaloupes lead to 30 deaths. A new set of recently released monoclonal antibodies to Listeria also contains several that are specific to the p60 protein that is secreted by the organism during growth in culture or in contaminated food. Thus these antibodies offer potential tools for the rapid detection of this food pathogen.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C179.jpg 112 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:38Listeria monoclonal antibodies
ProADM Product News 01

ProADM proven to be the best risk predictor

, 26 August 2020/in Product News /by 3wmedia

The new biomarker ProADM significantly improves risk assessment of patients suffering from lower respiratory tract infection (LRTI)

An early risk assessment of LRTI patients is essential for optimizing treatment and rational resource allocation. Adrenomedullin (ADM) has a significant presence in the course of LRTI and is strongly associated with a patient’s risk of mortality and severe complications. ADM reflects a patient’s risk profile while its elevation is independent of the LRTI etiology.
A robust method to assess ADM levels is the measurement of a stable surrogate marker, the mid-regional fragment of ProAdrenomedullin (MR-proADM). The only available automated immunoassay is from Thermo Fisher Scientific.

Features of ProADM (MR-proADM) measurement
• Directly reflective of ADM production in a 1:1 ratio
• Increased stability relative to ADM
• Reliably measurable with the automated Thermo Scientific B·R·A·H·M·S MR-proADM KRYPTOR immunoassay
• Well documented for clinical use
• Rapidly available to aid timely clinical decision-making (assay incubation time 29 minutes)
• Small sample volume (26µL)
• Measurement in EDTA plasma 

>> read more on www.thermoscientific.com/ProAdrenomedullin
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/ProADM-Product-News_01.jpg 166 100 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:23ProADM proven to be the best risk predictor
C206

Dickkopf Related Protein-1 (Dkk-1) ELISA

, 26 August 2020/in Product News /by 3wmedia

Dickkopf-1 is an inhibitor of the Wnt/beta-catenin signal pathway, which has been implicated in the development of several types of cancers. It has been suggested that Dkk-1 could be a useful serum biomarker for screening against a variety of cancers, and that anti-Dkk-1 antibodies are potential tools for diagnosis and treatment of cancer. Dkk-1 is particularly expressed in lung cancer cells; an increasing concentration of Dkk-1 is significantly associated with tumour progression and decreased survival in patients with lung cancer. Determination of both Dkk-1 and NSE levels can significantly increase sensitivity of small cell lung cancer diagnostics where a severe lack of an optimal diagnostic marker is widely reported. The use of Dkk-1 and cytokeratin 19 fragment also increased the sensitivity of detection of non-small cell lung cancer. High serum levels of Dkk-1 were found in patients with cancers of the oesophagus, pancreas, stomach, liver, bile duct, breast and cervix. Dkk-1 level increases early in prostate cancer development and in a stepwise manner in multistep hepatocarcinogenesis. A recently published study indicated that increased serum level and protein expression of Dkk-1 can be a marker and predictor of poor prognosis in patients with gastric cancer. A new DKK-1 ELISA kit has enhanced Biovendor’s cancer diagnostic test portfolio. The superior assay sensitivity is characterised by a LOD of 10 pg/mL.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C206.jpg 100 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:33Dickkopf Related Protein-1 (Dkk-1) ELISA
C186

Serum uromodulin ELISA

, 26 August 2020/in Product News /by 3wmedia

Uromodulin (Tamm-Horsfall protein) is the most abundant protein excreted in urine under physiological conditions. It is exclusively produced in the kidney and secreted into the urine via proteolytic cleavage. It has a protective role against urinary tract infections and renal stone formation. Mutations in the gene encoding uromodulin lead to rare autosomal dominant diseases, collectively referred to as uromodulin-associated kidney diseases. Genome-wide association studies identified uromodulin as a risk factor for chronic kidney disease (CKD) and hypertension, and suggested that urine uromodulin could represent a useful biomarker for the development of CKD. Recently, serum uromodulin determination exhibited characteristics superior to its measurement in the urine. Low serum uromodulin concentrations were associated with ANCA vasculitis, SLE, polycystic kidney disease, IgA nephropathy and preeclampsia. Using the cut-off 125.4 ng/mL uromodulin had a unique clinical sensitivity of 92.1% and specificity of 100.0% showing that it might be used as a screening nephropathy marker. BioVendor’s patent for the use of the serum uromodulin determination for the diagnosis of nephropathy is pending.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C186.jpg 113 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:41Serum uromodulin ELISA
C254 AniBiotech

Rapid diagnostic tests for pneumonia

, 26 August 2020/in Product News /by 3wmedia

The Biocard Mycoplasma pneumoniae IgM and Chlamydia pneumoniae IgM tests are lateral flow cassette tests for rapid detection of pneumoniae IgM antibodies in fingertip wholeblood samples, as well as in serum and plasma samples. The tests are CE-marked, easy and quick to perform: the results are available in 5–10 minutes. Most diagnosis of C. pneumoniae is done serologically and modified microimmuno-fluorescence methods are commonly used. Other test procedures, such as enzyme immunoassays and PCR methods, are also used, but all of these methods require trained personnel and a skilled interpreter, whereas a positive Biocard test result is a simple and rapid aid for the diagnosis of acute C. pneumoniae and M. pneumoniae infection. A typical test pack contains: 20 aluminium pouches containing a test cassette, 20 automatic lancets for obtaining a blood sample, 1 plastic vessel containing 20 pieces of 10 μl glass capillary, 20 tubes containing 0.5 ml of sample dilution buff er, 20 alcohol swabs, and an instruction leaflet.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C254_AniBiotech.jpg 97 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:17Rapid diagnostic tests for pneumonia
noema

Web-based clinical lab computerisation system

, 26 August 2020/in Product News /by 3wmedia

A new middleware for clinical chemistry, microbiology and molecular biology labs is available. Utilising a rule-based engine to deliver all-round control over laboratory workflow and sample processing, HALIA’s powerful functionality significantly improves laboratory efficiency, compliance and quality control. The middleware interface provides a complete web-based lab computerisation system, allowing central management and connection of all analysers through a single interface on any workstation. The user-configurable rule-based engine enables autoverification, sample routing and real-time clinical data capture and management for greater quality control. By supporting open automation systems and addressing issues such as regulatory compliance, workforce reductions and enhanced quality control, this middleware effectively meets the challenges facing lab managers. Responding to the increase in Point of Care Testing, a POCT Data Manager function is offered. This gives lab managers a real-time overview of all the data relating to multiple blood gas analysers or other devices, including instrument maintenance schedules and QC alerts. Detailed real-time data on total turnaround time (TAT) – a key performance indicator in large laboratories striving to increase throughput – is also provided. If a LIS/LIMS system goes down, the backup module allows manual input of sample information. Manual samples are then matched to LIS/LIMS data once the connection is restored.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/noema.jpg 150 150 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:25Web-based clinical lab computerisation system

ELISA for sarcopenia

, 26 August 2020/in Product News /by 3wmedia

Sarcopenia is defined as the loss of skeletal muscle mass and strength that can occur with advancing age. The current diagnosis of the disease is by dual-emission X-ray absorptiometry (DXA) scan, which measures lean body mass (LBM) in combination with functional tests. This cumbersome technique provides no information on the underlying cause of the loss of LBM. A novel biomarker is now available to identify the subgroup of patients (40%), whose sarcopenia is caused by excessive neurotrypsin activity. The NTCAF ELISA test has initially been developed for research purposes to aid the development of a treatment for the condition and could have potential as a companion diagnostic.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:20:232021-01-08 11:29:35ELISA for sarcopenia
Page 77 of 149«‹7576777879›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription